ÂÜÀòÂÒÂ×

May Meltzer is Scientific Intellectual Property (IP) lead at Prilenia. She is responsible for leading the scientific substantiation of Prilenia’s patent portfolio and managing Prilenia’s IP operations .

May is a Biochemist, with extensive experience in clinical pharmacology and drug delivery. Prior to Prilenia May was a Scientist at 1E Therapeutics. In that role, she worked on developing first-in-class RNA targeting therapeutics that address a wide array of indications in the fields of cancer, age-related disease and neurological diseases.

As a part of her PhD research, May developed a directed-evolution approach for high-throughput structural identification of G protein-coupled receptors (GPCR) for the development of new drugs targeting GPCRs. May was also working on engineering high affinity nanobody binders for orphan receptors and using her studies, she showed that utilizing computationally designed nanobody libraries result in the identification of well-expressed, functional, and specific nanobodys.